Researchers say the Schedule I ban could kill studies of a promising opioid treatment.
The DEA banned a drug some opioid users called a miracle
In short
The Drug Enforcement Administration formally placed a Schedule I ban on the substance. While some individuals recovering from opioid dependence viewed the treatment as a miracle, the new classification strictly curtails access. Researchers now warn that the federal restriction threatens to completely halt ongoing scientific studies. This roadblock derails further inquiry into what had previously shown promise as a viable therapeutic tool.
Key points
- Federal scheduling has effectively shut down legal avenues for studying this promising op…: Federal scheduling has effectively shut down legal avenues for studying this promising opioid treatment.
- Patients who previously relied on the substance view the decision as a setback for altern…: Patients who previously relied on the substance view the decision as a setback for alternative therapies.
- Scientific progress toward developing new medical interventions risks coming to a complet…: Scientific progress toward developing new medical interventions risks coming to a complete halt under federal restrictions.